World Journal of Surgery

, Volume 32, Issue 9, pp 2021–2025 | Cite as

Prevalence of Helicobacter pylori Seropositivity Among Patients Undergoing Bariatric Surgery: A Preliminary Study

  • Tolga Erim
  • Marcia R. Cruz-Correa
  • Samuel Szomstein
  • Evelio Velis
  • Raul RosenthalEmail author



The objective of this study was to compare the prevalence of Helicobacter pylori (HP) seropositivity in patients undergoing bariatric surgery with that of the general population.


H. pylori serologies, tested by ELISA, were collected on 240 morbidly obese patients seen at the Cleveland Clinic Florida and on 2444 randomly selected patients seen at the Cleveland Clinic Health System from 2003–2005.


H. pylori prevalence was 61.3% in the bariatric surgery group versus 48.2% in the general population control group (p < 0.001). Bariatric patients had a 1.7-fold increased likelihood of having HP when compared with controls (95% CI = 1.3–2.2). Age over 35 years was an independent risk factor for HP seropositivity (p < 0.01) in both the bariatric and control groups. There was no association found between body mass index and seropositivity within the bariatric group. There was no significant association between seropositivity and gender (p = 0.776). However, there was a significant association between seropositivity and race (p < 0.01). African-Americans had four times more (OR = 4.05) probability of having HP seropositivity than Caucasians (p < 0.01). Hispanics had almost three times (OR = 2.6) more probability of having HP seropositivity than Caucasians (p < 0.01).


The prevalence of HP seropositivity among bariatric patients is significantly higher than the general population control group.


Gastric Bypass Marginal Ulcer Bariatric Patient Gastric Bypass Patient Bismuth Subcitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    National Center for Health Statistics NHANES IV Report.
  2. 2.
    Flegal KM, Carroll MD, Ogden CL et al (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727PubMedCrossRefGoogle Scholar
  3. 3.
    Buchwald H, Avidor Y, Braunwald E et al (2004) Bariatric surgery: A systematic review and meta-analysis. JAMA 292(14):1724–1737PubMedCrossRefGoogle Scholar
  4. 4.
    Marshall BJ, Windsor HM (2005) The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 89:313–344PubMedCrossRefGoogle Scholar
  5. 5.
    International Agency for Research on Cancer (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61:177–241Google Scholar
  6. 6.
    Ramaswamy A, Lin E, Ramshaw BJ et al (2004) Early effects of Helicobacter pylori infection in patients undergoing bariatric surgery. Arch Surg 139:1094–1096PubMedCrossRefGoogle Scholar
  7. 7.
    Schirmer B, Erenoglu C, Miller A (2002) Flexible endoscopy in the management of patient undergoing Roux-en-Y gastric bypass. Obes Surg 12:634–638PubMedCrossRefGoogle Scholar
  8. 8.
    Papasavas PK, Gagné DJ, Donnelly PE et al (2008) Prevalence of Helicobacter pylori infection and value of preoperative testing and treatment in patients undergoing laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 4(3):383–388PubMedCrossRefGoogle Scholar
  9. 9.
    Renshaw AA, Rabaza JR, Gonzalez AM et al (2001) Helicobacter pylori infection in patients undergoing gastric bypass surgery for morbid obesity. Obes Surg 11(3):281–283PubMedCrossRefGoogle Scholar
  10. 10.
    Fontana L, Eagon JC, Colonna M et al (2007) Impaired mononuclear cell immune function in extreme obesity is corrected by weight loss. Rejuvenation Res 10(1):41–46PubMedCrossRefGoogle Scholar
  11. 11.
    O’Rourke RW, Kay T, Lyle EA et al (2006) Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol 146(1):39–46PubMedCrossRefGoogle Scholar
  12. 12.
    Amar S, Zhou Q, Shaik-Dasthagirisaheb Y et al (2007) Diet-induced obesity in mice causes changes in immune responses and bone loss manifested by bacterial challenge. Proc Natl Acad Sci U S A 104(51):20466–20471PubMedCrossRefGoogle Scholar
  13. 13.
    Smith AG, Sheridan PA, Harp JB et al (2007) Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr 137:1236–1243PubMedGoogle Scholar
  14. 14.
    Wu MS, Lee WJ, Wang HH et al (2005) A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med 165(13):1552–1555PubMedCrossRefGoogle Scholar
  15. 15.
    Kuipers EJ, Klinkenberg-Knol EC, Vandenbroucke-Grauls CM et al (1997) Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scand J Gastroenterol 223:28–34Google Scholar
  16. 16.
    Ohkuma K, Okada M, Murayama H et al (2000) Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 15:1105–1112PubMedCrossRefGoogle Scholar
  17. 17.
    Asaka M, Sugiyama T, Nobuta A et al (2001) Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter 6:294–299PubMedCrossRefGoogle Scholar
  18. 18.
    Malfertheiner P, Megraud F, O’Morain C et al (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56(6):772–781PubMedCrossRefGoogle Scholar
  19. 19.
    Safatle-Ribeiro AV, Kuga R, Iriya K, Ribeiro et al (2007) What to expect in the excluded stomach mucosa after vertical banded Roux-en-Y gastric bypass for morbid obesity. J Gastrointest Surg 11(2):133–137PubMedCrossRefGoogle Scholar
  20. 20.
    Kihira K, Satoh K, Saifuku K et al (1996) Endoscopic topical therapy for the treatment of Helicobacter pylori infection. J Gastroenterol 31(Suppl 9):66–68PubMedGoogle Scholar
  21. 21.
    Satoh K (1996) Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents. Scand J Gastroenterol Suppl 214:56; discussion 57–60PubMedCrossRefGoogle Scholar
  22. 22.
    Nwokolo CU, Mistry P, Pounder RE (1990) The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate). Aliment Pharmacol Ther 4:163–169PubMedCrossRefGoogle Scholar
  23. 23.
    Whitehead MW, Phillips RH, Sieniawska CE et al (2000) Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia. Helicobacter 5:169–175PubMedCrossRefGoogle Scholar
  24. 24.
    Moshkowitz M, Konikoff FM, Peled Y et al (1995) High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 36:845–847 PubMedCrossRefGoogle Scholar
  25. 25.
    Sheu BS, Yang HB, Su IJ et al (1996) Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 44:683–688PubMedCrossRefGoogle Scholar
  26. 26.
    Megraud F, Brassens Rabbe MP, Denis F et al (1989) Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 27:1870–1873PubMedGoogle Scholar
  27. 27.
    Woodward M, Morrison C, McColl K (2000) An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 53:175–181PubMedCrossRefGoogle Scholar
  28. 28.
    Go MF (2002) Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 16(Suppl 1):3–15PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2008

Authors and Affiliations

  • Tolga Erim
    • 1
  • Marcia R. Cruz-Correa
    • 2
  • Samuel Szomstein
    • 3
  • Evelio Velis
    • 4
  • Raul Rosenthal
    • 3
    Email author
  1. 1.Department of GastroenterologyCleveland Clinic FloridaWestonUSA
  2. 2.Medicine & BiochemistryUniversity of Puerto Rico Comprehensive Cancer CenterSan JuanPuerto Rico
  3. 3.Division of Minimally Invasive and Bariatric SurgeryThe Bariatric Institute, Cleveland Clinic FloridaWestonUSA
  4. 4.Health Services Administration Master ProgramBarry UniversityMiamiUSA

Personalised recommendations